InflaRx Reports Phase 1 Safety and C5a Blockade Results for Izicopan

The Phase 1 study in 86 healthy participants reported no serious adverse events and greater than 90% C5a-induced CD11b blockade after single doses of at least 10 mg. The results had been announced previously.